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Abstract: The use of HIV protease inhibitors (PIs) as part of antiretroviral therapy in the treatment of HIV-1 infection 
may be associated with an increased risk of bleeding. This prospective, randomized, open-label trial in healthy volunteers 
compared the effects of tipranavir/ritonavir (TPV/r), darunavir/ritonavir (DRV/r), and ritonavir (RTV) alone on platelet 
aggregation after a single dose and at steady-state concentrations. Subjects were selected on the basis of normal platelet 
aggregation and arachidonic acid (AA)-induced platelet aggregation inhibition after administration of a single 325-mg 
dose of aspirin. All 3 PI therapies were administered twice daily for 10 days. 
In some but not all subjects, TPV/r inhibited AA-induced platelet aggregation and prolonged PFA-100
® closure time with 
collagen-epinephrine cartridge, which was of lesser magnitude and consistency compared with aspirin, but greater when 
compared to DRV/r and RTV. At least 2 subjects in each treatment arm showed complete inhibition of AA-induced 
platelet aggregation on treatment, and the magnitude of change in all platelet-function tests did not correlate with PI 
plasma concentrations. Effects of TPV/r on platelet aggregation were reversed 24 hours after the last TPV/r dose. None of 
the PI treatments tested were associated with increases in bleeding time, decreases in plasma coagulation factors, or 
increase in fibrinolysis. There was large inter-patient variability in antiplatelet effect for all PI treatments, ranging from no 
effect to complete inhibition of AA-induced platelet aggregation. 
Keywords: Aggregation, aspirin, bleeding time, coagulation, fibrinolysis, platelet, protease inhibitor. 
INTRODUCTION 
  Long-term combination antiretroviral therapy (cART) is 
associated with various complications, including 
cardiovascular events [1], lipodystrophy [2], and non-AIDS-
defining cancers [3]. 
  Tipranavir (TPV), coadministered with low-dose 
ritonavir (TPV/r), is indicated for cART of HIV-1 infected 
patients who are treatment-experienced and infected with 
HIV-1 strains resistant to more than 1 protease inhibitor (PI) 
[4]. Rare bleeding events, including fatal and nonfatal 
intracranial hemorrhage (ICH) have been reported in HIV-
infected patients receiving TPV/r or other PIs as part of 
cART [5-8], and an increased incidence of bleeding events in 
HIV-positive hemophiliacs treated with PIs has been 
observed [7,8]. The incidence of ICH events in TPV/r-
treated patients is low, 0.26/100 person-years of exposure, or 
13 cases of ICH in 6,840 patients in TPV/r pre-approval 
trials [6], and this incidence for ICH is similar to that of 
HIV-infected patients who received a non-TPV/r-containing 
cART based on retrospective analyses of 2 large patient 
cohorts (N > 78,000 HIV-infected patients combined) from 
the California state Medicaid program (Medi-Cal) and the 
U.S. Veterans Healthcare System (VA) [9,10]. 
  The mechanism by which TPV or other PIs may increase 
the risk of bleeding is not known. Results from a 
retrospective analysis of plasma samples from patients in the 
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RESIST studies showed that neither TPV/r nor comparator 
PI/r treatments produced decreases in levels or activity of 
vitamin K-dependent coagulation factors, factor V, and 
prolongation of prothrombin time (PT) and activated partial 
thromboplastin time (aPTT) [11]. In a recent study with 
platelet-rich plasma (PRP) taken from 5 HIV-infected 
patients receiving TPV/r-containing cART, inhibition of 
collagen- (p<0.001 at 4 hours after dosing) and adenosine 
diphosphate (ADP) (non- statistically significant)-stimulated 
platelet aggregation was observed [12]. 
  The current study was undertaken to prospectively 
examine the effects of TPV/r on platelet function and plasma 
biomarkers of coagulation and fibrinolysis in healthy 
volunteers and to compare these effects with those of 
ritonavir (RTV) and darunavir (DRV) coadministered with 
RTV (DVR/r). DRV was selected as a comparator PI 
because, similar to TPV, it is coadministered with RTV and 
also indicated and frequently used for the treatment of HIV-1 
infection in antiretroviral treatment-experienced adult patients 
infected with HIV-1 strains resistant to more than 1 PI. 
METHODS 
Study Design and Treatments 
  This was a prospective, open-label, randomized, and 
controlled single-center trial in healthy volunteers, in which 
36 subjects were initially randomized 1:1:1 to treatment with 
TPV/r, DRV/r, or RTV. Due to 7 early discontinuations in 
the TPV/r arm, 11 additional subjects were allocated to the 
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  Following informed consent, subjects were screened at 
visit 1, baseline platelet-function tests were obtained for each 
eligible subject at visit 2, and at visit 3, each subject received 
a single dose of aspirin 325 mg followed by determination of 
platelet function after 4 hours. After a washout period of  
14 days, subjects were randomized to 1 of 3 treatment 
groups. Group 1 received TPV/r 500 mg/200 mg, group 2 
received DRV/r 600 mg/100 mg, and group 3 received RTV 
100 mg monotherapy, each administered twice daily for 10 
days. Pharmacodynamic (PD) biomarkers were assessed 
prior to PI dosing, after 1 day of dosing (day 1), after the last 
morning dose on day 10 (steady state), and 1 and 2 days after 
the last PI dose. Subjects were confined to the study unit for 
2 overnight stays for aspirin dosing, and for an additional 13 
overnight stays for the randomized treatment and study 
assessments. 
Study Subjects 
  The study protocol and related documents were approved 
by the institutional review board. Healthy men and women 
between 18 and 50 years of age who met all inclusion 
criteria (see Table 1) were eligible to participate in this 
study. Of the 280 subjects screened, 52 met study inclusion 
criteria prior to receiving a single 325-mg dose of aspirin. 
Subjects were excluded from the study if they used an 
investigational agent within 30 days prior to visit 2; donated 
blood or plasma within 30 days prior to visit 2; used aspirin 
or any nonsteroidal anti-inflammatory drug, cyclooxygenase-
2 (COX-2) inhibitors, dipyridamole, clopidogrel, ticlopidine, 
or other antiplatelet drug prior to visit 2; had peptic 
ulceration or a history thereof; had an active bleeding 
disorder or history thereof; used any over-the-counter 
medication within 7 days prior to visit 2 or were currently 
receiving any prescription drug; used proton pump inhibitors 
within 14 days prior to visit 2; or had vitamin E intake 
 > 60 mg/day within 30 days prior to visit 2 or during the 
study. Women were excluded if they were pregnant, 
breastfeeding, not willing to use a barrier method of 
contraception from screening through the end of study, or 
were taking any hormonal therapy. The subjects were 
specifically instructed not to use any nonprescription 
medication during the study. 
Study Objectives 
  The primary objective of this study was to determine the 
effect of steady-state plasma concentrations of TPV/r on 
platelet-function tests and biomarkers of coagulation and 
fibrinolysis. The secondary objective was to compare the 
effects of TPV/r, DRV/r, and RTV on these markers. 
Additional comparisons were made for effects on platelet 
Table 1.  Patient Demographics and Baseline Characteristics 
 
  TPV/r 
n = 23 
DRV/r 
n = 12 
RTV 
n = 12 
Total 
N = 47 
Gender, N (%) 
 Men 
 Women   
 
14 (60.9) 
9 (39.1) 
 
7 (58.3) 
5 (41.7) 
 
7 (58.3) 
5 (41.7) 
 
28 (59.6) 
19 (40.4) 
Ethnicity, N (%) 
  Not Hispanic or Latino 
  Hispanic or Latino 
 
20 (87.0) 
3 (13.0) 
 
11 (91.9) 
1 (8.3) 
 
10 (83.3) 
2 (16.7) 
 
41 (87.2) 
6 (12.8) 
Mixed race, N (%) 
 Yes 
 No 
 
1 (4.3) 
22 (95.7) 
 
0 
12 (100) 
 
0 
12 (100) 
 
1 (2.1) 
46 (91.9) 
Race, N (%) 
 White 
 Black 
 Asian 
 
5 (21.7) 
17 (73.9) 
1 (4.3) 
 
1 (8.3) 
11 (91.7) 
0 
 
4 (33.3) 
7 (58.3) 
1 (8.3) 
 
10 (21.3) 
35 (74.5) 
2 (4.3) 
Mean  age,  y  32.9 34.0 31.8 32.9 
Mean body mass index kg/m
2, %  30 (minimum-maximum)
  27.7/22% 
(21.5-36.3) 
27.8/25% 
(22.4-40.2) 
26.5/25% 
(20.5-30.6) 
27.4/23% 
(20.5-40.2) 
Smoking history, N (%) 
 Never  smoked 
 Ex-smoker 
 Current  smoker 
 
19 (82.6) 
4 (17.4) 
0 
 
10 (83.3) 
2 (16.7) 
0 
 
10 (83.3) 
2 (16.7) 
0 
 
34 (72.3) 
13 (27.7) 
0 
Alcohol history, N (%) 
 Non-drinker 
 Average  consumption 
 Excessive  consumption 
 
14 (60.0) 
9 (39.1) 
0 
 
10 (83.3) 
2 (16.7) 
0 
 
10 (83.3) 
2 (16.7) 
0 
 
34 (72.3) 
13 (27.7) 
0 
Inclusion criteria: Healthy men and women aged 18-50 years who agreed to abstain from alcohol, recreational drugs, tobacco products, ingestion of grapefruit juice or Seville 
oranges during the study; were negative for HIV-1 and hepatitis C antibody, or hepatitis B surface antigen; and had normal platelet count  125,000/mm
3, hemoglobin  11.0 g/dl, 
prothrombin time  1 x upper limit of normal (ULN), and activated partial thromboplastin time  1 x ULN. Effect of Tipranavir on Markers of Platelet Function  Current HIV Research, 2011, Vol. 9, No. 4    239 
functions for single-dose aspirin versus TPV/r in individual 
subjects. 
Platelet-Function Tests 
  Platelet aggregation tests used light transmission 
aggregometry. Blood samples from healthy volunteers were 
collected from antecubital veins into vacutainer tubes 
containing citrate. Platelet-rich plasma was prepared 
immediately by centrifugation at 1200g, and platelet 
aggregation studies were performed within 1 hour in the 
Hematology and Coagulation Laboratories at Johns Hopkins 
University using a Chrono-log Whole Blood Lumi-
Aggregometer
® (model 560-Ca) as previously described 
[13]. Platelet aggregation was stimulated with 0.5 mM 
arachidonic acid (AA), 5 M ADP, and 5 g/ml collagen, 
and expressed as the percentage of light transmittance 
change from baseline using platelet-poor plasma as a 
reference at the end of recording time. Platelet aggregation 
curves were analyzed according to internationally 
established standards using Aggrolink
 software (unless 
otherwise stated, all equipment and reagents from Chrono-
log Corp., Havertown, PA). 
  Closure time (CT) of platelet-rich plasma was determined 
in a PFA-100
® platelet-function analyzer (Dade Behring, 
Miami, FL) using collagen/epinephrine (CEPI) and 
collagen/ADP standard test cartridges [13]. Bleeding time 
was measured using the Surgicutt
® fully automated incision-
making device for bleeding time determination (ITC, Edison, 
NJ), and package instructions were followed by personnel 
performing the tests. A small incision was made with the 
instrument on the subject’s forearm, and blood was gently 
blotted every 30 seconds, without touching the incision. The 
bleeding time was reported out to the nearest 30 seconds. 
 Urinary  thromboxane  B2  (TXB2) metabolites were 
measured at Covance Laboratories using TXB2 Express 
Enzyme Immunoassay Monoclonal Antibody (Cayman 
Chemical Company, Ann Arbor, MI). 
Markers of Coagulation and Fibrinolysis 
  Prothrombin time; aPTT; fibrinogen; von Willebrand 
antigen; anti-thrombin III antigen/activity; factors II, VII, IX, 
and X activity; plasminogen activity; -2 antiplasmin; D-
dimer; and plasminogen activator inhibitor (PAI-1) were 
measured at Covance Laboratories (Indianapolis, IN). 
Plasma Concentrations of Tipranavir, Darunavir, and 
Ritonavir 
  Blood samples for determination of concentrations of 
TPV, DRV, and RTV in plasma were collected in 5-ml 
vacutainer collection tubes containing ethylene diamino 
tetraacetic acid (EDTA). Trough plasma samples for the PIs 
were collected prior to the morning dose on days 1, 2, 3, and 
6, and at day 10 (steady state) after initiation of treatment. 
Steady-state pharmacokinetic (PK) profiles included 6 timed 
samples within 12 hours of the morning dose of PI on day 
10. Post last-dose plasma samples were collected 24 hours 
and 48 hours after the last dose. 
  Plasma concentrations of TPV, DRV, and RTV were 
measured using validated and quality-controlled liquid 
chromatography coupled with tandem mass spectrometry 
(LC/MS/MS) performed by BASi Analytical Laboratories 
(West Lafayette, IN). 
Endpoints 
  The primary PD endpoint was the inhibition of platelet 
aggregation by AA, measured as area under the curve (AUC) 
at steady state (day 10), expressed as percent reduction from 
baseline. Secondary endpoints included change from 
baseline at days 1, 10, 11 (i.e., 1 day post treatment), and 12 
(2 days post treatment) for 3 sets of biomarkers: (1) platelet 
function biomarkers: platelet aggregation in response to AA, 
ADP, and collagen; PFA-100 test with CEPI reported as CT 
in seconds; PFA-100 test with collagen/ADP reported as CT 
in seconds; urinary TXB2 metabolites; and bleeding time; (2) 
coagulation biomarkers: aPTT, prothrombin time, 
fibrinogen, von Willebrand and antithrombin III antigens and 
activity; and coagulation factors II, VII, IX, and X; and (3) 
fibrinolytic biomarkers: plasminogen activity, -2 
antiplasmin, D-dimer, and PAI-1. Effects of the single dose 
of aspirin on markers of platelet aggregation were 
determined at 4 hours after aspirin dosing (visit 3). The PI 
effects were compared with the aspirin effects as day 1 PI 
change versus aspirin change and day 10 PI change versus 
aspirin change. 
 PK  parameters  measured for exploration of the PD/PK 
relationship included maximum drug concentration (Cmax), 
minimum drug concentration (Cmin), and AUC0-12 for the 3 
PIs (TPV, DRV, and RTV). 
Safety Assessment 
  Safety endpoints included treatment-emergent adverse 
events (AEs) and laboratory abnormalities. Standard safety 
reporting methods were used in this study. 
Statistical Methods 
  The primary analysis consisted of computing the 95% 
confidence interval (CI) for the percent reduction from 
baseline to steady state in AA AUC for TPV/r subjects, 
based on a normal distribution. The bounds of this CI were 
compared to a 50% reduction. The 50% reduction was 
empirically chosen to distinguish between subjects with clear 
changes in laboratory markers of aggregation and those with 
borderline or no effect. These analyses were also repeated 
for other time points as well as in DRV/r- and RTV-treated 
subjects. In addition, percentage of subjects with  50% 
reduction in AA AUC was tabulated and differences between 
the groups were analyzed using a Fisher’s exact test. 
Secondary analyses consisted of summary statistics of all 
biomarkers at all time points. Using 2-sided t-tests, changes 
in markers of platelet aggregation, coagulation, and 
fibrinolysis from baseline to steady state were compared in 
subjects receiving TPV/r versus comparator PI treatments. 
Linear regression analyses were performed to explore the 
relationships between all studied biomarkers and PK 
parameters (Cmax, AUC0-12, Cmin at steady state, and Cmin at 
day 1 of treatment and 24 hours and 48 hours after end of 
treatment). For select PD markers, comparisons were made 
with PK parameters to explore whether differences in TPV 240    Current HIV Research, 2011, Vol. 9, No. 4  Kort et al. 
levels accounted for differences observed in their platelet-
function tests. 
  Effects on markers of platelet aggregation observed in 
the different PI-treatment groups were compared with the 
effects of single-dose aspirin in the same subject, using a 
Wilcoxon-Mann-Whitney test. 
  The number of patients in each arm was calculated in 
order to have enough power to show that the 95% CI for the 
mean percent reduction from baseline in AA AUC does not 
include a 50% reduction. Assuming a mean AA AUC of 200 
Vs at baseline and a standard deviation (SD) of 20 (both 
conservatively estimated from Van Ryn et al. 2004 [14], and 
an absolute mean reduction of 80 Vs (i.e., a 40% reduction in 
AA AUC) at steady state, 12 subjects would provide 88% 
power to conclude that the reduction in AA AUC was not 
deemed relevant (i.e., CI will not include a 50% reduction). 
RESULTS 
Subject Disposition and Demographic Characteristics 
  Subject disposition is shown in Fig. (1). Of 280 subjects 
screened, 52 received aspirin at visit 3; 47 subjects received 
at least 1 dose of PI and 5 subjects received aspirin but no 
other study medication. In all, 36 subjects were randomized 
to TPV/r (n = 12), DRV/r (n = 12), or RTV (n = 12); 11 
subjects were allocated to TPV/r as replacements for 7 
subjects who discontinued early in the TPV/r arm. In 
response to AA, 45 of 47 subjects demonstrated a return to 
normal in platelet aggregation after aspirin administration 
and following a washout period, and were considered 
evaluable. Overall, demographic characteristics were well 
matched between treatment arms (Table 1). Of the 47 treated 
subjects, 60% were men, 75% were black, the mean age was 
33 years, and 23% had a body mass index (BMI)  30 kg/m
2 
indicating obesity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1).  Subject disposition. 
*One subject missed only the last 
dose and the steady-state PK and PD data were considered valid, 
resulting in 16 evaluable subjects for steady-state analyses, but only 
15 subjects for 24 and 48 hours post-dose analyses. 
†Two subjects 
did not demonstrate return of platelet aggregation in response to 
AA after post-aspirin washout period. 
Light Transmission Aggregometry Platelet Aggregation 
Tests 
  AA-induced platelet aggregation in response to a single 
dose of aspirin and over the course of treatment with TPV/r, 
DRV/r, and RTV is shown in Fig. (2A). AA-induced platelet 
aggregation was completely inhibited by aspirin in all 
subjects in each PI-treatment group, whereas the effect of 
each of the PI treatments was highly variable at each on-
treatment time point. For the primary analysis, TPV/r at 
steady-state concentrations lowered AA-induced platelet 
aggregation by a mean of 43% (SD, 57.5; 95% CI, 12.6-
73.9; Fig. (2B); this effect was significantly different 
compared with subjects treated with DRV/r but not versus 
subjects in the RTV-treatment group. At steady state, 43.8% 
(7/16) of subjects in the TPV/r group had  50% inhibition 
of platelet aggregation in response to AA versus 8.3% (1/12) 
in the DRV/r arm and 16.7% (2/12) in the RTV arm (Fisher 
exact p-values of 0.0882 and 0.2232 for comparing TPV/r to 
DRV/r and RTV, respectively). Inhibition of platelet 
aggregation was reversed in all subjects 24 hours after the 
last dose of PI treatment. AA-induced platelet aggregation of 
 50% inhibition was observed in a larger proportion of 
subjects (66.7% [14/21]) after 1 day of TPV/r treatment 
compared with steady state. The day 1 proportions of TPV/r 
patients with AA-induced platelet aggregation were 
significantly higher than DRV/r (25.0% [3/12]; p=0.0324) 
and RTV (8.3% [1/12]; p=0.0028). 
 
 
 
 
 
 
 
Fig. (2). ( A) Platelet aggregation in response to AA over time 
(mean AUC ± SD [AUC unit]); the arrow signifies steady state. (B) 
Comparison of platelet aggregation in response to AA at steady 
state between treatment groups. TX = treatment. 
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  Treatment with TPV/r, DRV/r, and RTV did not have an 
effect on platelet aggregation in response to ADP and 
collagen (Fig. 3). Only treatment with aspirin inhibited 
collagen-induced platelet aggregation significantly from 
baseline, and reduced collagen-induced platelet aggregation 
below reference range in 49% (22/45) of all subjects in the 3 
PI-treatment groups combined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Platelet aggregation in response to ADP and collagen 
over time (mean AUC ± SD [AUC unit]). TX = treatment. 
Other Platelet Function Tests 
  Mean values for other platelet function tests at various 
time points for subjects treated with TPV/r are shown in 
Table 2. TPV/r had no significant effect on bleeding time or 
PFA-100 collagen/ADP CT. The PFA-100 CEPI CT was 
increased above the reference range (94-193 seconds) in 
38% (8/21) and 25% (4/16) of TPV/r-treated subjects on day 
1 and day 10 after dosing, respectively. Prolongation of the 
CEPI CT was reversed to normal values 24 hours after the 
last TPV/r dose in all subjects in that group. A total of 7 of 
14 and 5 of 7 TPV/r-treated subjects with  50% inhibition 
of platelet aggregation in response to AA on day 1 and day 
10, respectively, had no increase in PFA-100 CEPI CT 
above the normal reference range at the same time points. 
Thus, there was only partial overlap in effects of TPV/r on 
AA-induced platelet aggregation and CEPI CT. Urinary 
TXB2 metabolites in the TPV/r group were significantly 
increased from baseline after 10 days of treatment and 
remained elevated 48 hours after the last TPV/r dose. 
  In a comparison of treatment arms, PFA-100 CEPI CT 
(mean change ± SD in seconds) in the TPV/r group (+92 ± 
73) was the only secondary platelet function marker with a 
change from baseline that was significantly and 
meaningfully different compared with DRV/r (-3.4 ± 15.2; 
p=0.0001) and RTV (-11.2 ± 19.9; p<0.0001) on day 1 of 
dosing. However, the mean (± SD) CEPI CT for TPV/r 
subjects did not change substantially above the upper limit of 
the reference range after 1 day of TPV/r dosing (193.1 ± 92 
seconds) (Table 2). The prolongation of the PFA-100 CEPI 
CT (mean increase ± SD) was significantly greater with 
aspirin (+124 ± 71 seconds) than with steady-state TPV/r 
(+56 ± 55 seconds; p=0.0135); mean ± SD absolute CEPI 
CT at steady-state TPV/r was 161.7 ± 56 seconds. Single-
dose aspirin prolonged CEPI CT in 81% (17/21) of TPV/r 
subjects to above reference range (mean ± SD CEPI CT after 
single-dose aspirin, 249 ± 69 seconds). 
  A summary of within-subject comparisons of effects at 
steady state with aspirin versus TPV/r for the 4 selected 
platelet aggregation markers is shown in Fig. (4). With the 
exception of the absence of significant effects of aspirin and 
TPV/r on ADP-induced platelet aggregation, the magnitude 
of inhibition of AA- and collagen-induced platelet 
aggregation and prolongation of CEPI CT was significantly 
greater following a single dose of aspirin when compared 
with the effect of TPV/r at steady-state levels. 
 
 
 
 
 
 
 
 
 
Fig. (4). Within-subject comparison of aspirin and TPV/r (at steady 
state) on platelet aggregation. 
Markers of Coagulation and Fibrinolysis 
  Changes of mean values for coagulation and fibrinolysis 
biomarkers at various time points for subjects treated with 
TPV/r are shown in Table 3. Due to the multitude of tests 
being conducted without any adjustment for multiplicity, 
these results should be interpreted with caution as the 
probability of a chance finding with so many tests is high. 
Certainly, causal relationships cannot be inferred until the 
results are confirmed in another study. 
  There were statistically significant elevations from 
baseline to day 1 observed in plasminogen activity and PAI 
activity. Statistically significant changes from baseline to 
day 10 were observed in most of the coagulation and 
fibrinolysis biomarkers studied (12 out of 14 parameters) and 
these changes were mostly maintained until 48 hours after 
administration of the last dose of study drug. Only 3 markers 
were changed in the direction that could potentially decrease 
coagulation: antithrombin III antigen (increase from baseline 
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mean of 104.29% to steady state mean of 134.44%), 
antithrombin III activity (increase from baseline mean of 
100.57% to steady state mean of 124.06%), and plasminogen 
activity (increase from baseline mean of 116.38% to steady 
state mean of 150.13%). All other markers were changed in 
the opposite direction. 
  There were several statistically significant differences in 
change from baseline to days 1 and 10 of treatment in TPV/r 
subjects compared with DRV/r and RTV subjects (Table 4). 
These differences were minor at day 1: a) aPTT larger mean 
decrease in the RTV group (-2.44 ± 2.29 seconds) than in the 
TPV/r group (-0.52 ± 1.48 seconds) and b) mean increase in 
Factor II in the DRV/r group (13.75 ± 16.8%) versus 
marginal mean decrease in the TPV/r group (2.90 ± 21.2%). 
Changes from baseline to day 1 in both of these factors in the 
TPV/r group were not statistically significant (Table 3). 
  At day 10 there were more markers that demonstrated 
statistically significant differences between treatment groups. 
The increases in antithrombin III antigen, antithrombin III 
activity, and plasminogen activity were higher in the TPV/r 
group in comparison to the DRV/r group for the first marker. 
There were statistically significant differences between the 
TPV/r and RTV groups in fibrinogen and von Willebrand 
factor antigen. In addition, PAI-1 activity was increased to a 
lesser degree in the RTV group in comparison to the TPV/r 
group, and Factor X was increased to a lesser degree in the 
TPV/r group in comparison to the DRV/r group. With the 
exception of small increases in antithrombin III and 
plasminogen, mild increases in other studied factors with 
TPV/r suggests no increased risk for bleeding due to 
impeded coagulation or increase in fibrinolysis. 
Pharmacokinetic–Pharmacodynamic Evaluation 
  Regression analyses of TPV/r PK parameters (including 
log-transformed trough levels [Cmin] at all studied time 
points,  Cmax and AUC at steady state, and all tested PD 
biomarkers) did not provide for any consistent association 
between TPV/r PK parameters and effects on markers of 
platelet aggregation, fibrinolysis, and coagulation (data not 
shown). Higher plasma TPV trough concentrations were 
observed after 1 day of dosing (geometric mean 47.8 M, 
CV% 46.9) compared with steady state (geometric mean 
24.1  M, CV% 80.5); however, there was no correlation 
between TPV trough plasma concentrations and inhibition of 
AA-induced platelet aggregation. In 6 out of 14 and 4 out of 
7 subjects with ex vivo   50% inhibition of AA-induced 
platelet aggregation after 1 day and 10 days of TPV/r 
administration, respectively, TPV trough levels were 
consistently below the group mean. Conversely, 4 out of 7 
subjects and 2 out of 9 subjects did not exhibit > 50% in ex 
vivo inhibition of AA-induced platelet aggregation after 1 
day and 10 days of TPV/r administration, respectively, and 
showed consistently higher TVP trough levels above the 
group mean (not shown). Similarly, there was no correlation 
between studied PK parameters (Cmax,  Cmin, and AUC0-12) 
and increases in CEPI CT with TPV/r treatment. 
Safety 
  Safety evaluations were performed on all enrolled 
subjects. All subjects in the DRV/r (n = 12) and RTV (n = 
12) arms completed 10 days of treatment, whereas 70% 
(16/23) of subjects receiving TPV/r completed the 10-day 
treatment. 
  In the TPV/r arm, 70% of subjects (16/23) had at least 1 
AE, including 14 subjects who had AEs that were considered 
treatment-related. A total of 7 subjects in TPV/r arm 
discontinued treatment early: 6 subjects due to AE and 1 
subject because of non-compliance with the protocol 
(potential use of aspirin or other anti-platelet drugs during 
the washout period). Of 6 subjects who discontinued 
treatment early because of AEs, 5 subjects (2 of these were 
of severe intensity) had asymptomatic alanine 
aminotransferase (ALT) elevations (range, 89-334 U/l) that 
were > 2.5 times the upper limit of normal (ALT 6-34 U/l), 
that was pre-specified treatment discontinuation criterion, 
and 1 subject discontinued due to a severe pruritic rash. All 6 
subjects with early discontinuation due to AEs completely 
recovered from these AEs during follow-up. 
  TPV trough concentrations prior to discontinuation in 
these subjects were substantially elevated (range, 54.3-197.5 
M) above the group mean (see above). In the other 2 PI 
arms, 50% (6/12) of subjects receiving DRV/r and 58% 
(7/12) receiving RTV had at least 1 AE and 3 and 5 subjects, 
respectively, had AEs defined as related to treatment. No 
subjects in the DRV/r or RTV groups discontinued because 
of AEs. 
  The most commonly reported AEs in the TPV/r, DRV/r, 
and RTV groups, respectively, included laboratory 
abnormalities (52%, 8%, 25%), gastrointestinal disorders 
(35%, 25%, 33%), nervous system disorders (13%, 42%, 
Table 2.  Course and Change from Baseline for Other Platelet Functions in the TPV/r Group 
 
Biomarker (Reference Range)    Baseline 
n = 21 
Day 1 
n = 21 
Day 10 
n = 16 
24 h After Last Dose 
n = 15 
48 h After Last Dose 
n = 15 
Bleeding time, min (< 8 min)  Mean 
p* 
5.29 
– 
6.48 
0.056 
5.47 
0.694 
5.73 
0.410 
4.67 
0.104 
Urinary TxB2 metabolites, pg/mg (> 1500)  Mean 
p* 
2748 
– 
2458 
0.123 
3609 
0.019 
3374 
0.116 
4272 
0.027 
PFA-100 collagen/epinephrine, s (94-193)  Mean 
p* 
101.1 
– 
193.1 
<0.0001 
161.7 
0.0011 
118.9 
0.097 
108.8 
0.756 
PFA-100 collagen/ADP, s (71-118)  Mean 
p* 
70.62 
– 
73.81 
0.366 
74.38 
0.619 
74.33 
0.864 
70.53 
0.110 
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17%), and skin disorders (9%, 17%, 25%). There were no 
serious AEs or deaths in this trial. 
DISCUSSION 
  Therapeutic doses of tipranavir in combination with 
ritonavir (TPV/r) at steady-state plasma concentrations 
significantly reduced ex vivo AA-induced platelet 
aggregation by a mean of 43% (AUC) in this randomized, 
controlled trial in healthy volunteers. This effect was more 
readily apparent after the first day of TPV/r administration 
when compared to steady state, but was not correlated with 
higher plasma TPV trough concentrations. The higher TPV 
concentrations on day 1 of treatment is explained by the 
immediate and potent inhibition of cytochrome P450 3A4 
enzyme by RTV, which was followed by later enzyme 
induction due to TPV [15]. Independent of TPV plasma 
concentrations, we observed large differences among   
subjects (e.g., inhibition of  50% versus no inhibition) on ex 
vivo AA-stimulated platelet aggregation, which may suggest 
differences in subject predisposition to TPV/r-mediated 
inhibition of AA-induced platelet aggregation. Similarly, and 
in addition to TPV/r effect, unknown factors may explain the 
abnormal PFA-100 CEPI CT tests in a minority of subjects 
who received TPV/r. 
  In our group of healthy volunteers, multiple dosing with 
TPV/r did not inhibit ex vivo collagen-, ADP-, and PFA-100 
collagen/ADP-stimulated platelet aggregation function tests. 
These findings are in contrast to a recent study in which 
collagen- or ADP-stimulated platelet aggregation was inhibited 
in PRP from 5 HIV-infected patients taking TPV/r and in PRP 
taken from  5 healthy volunteers after it was spiked with 
different TPV concentrations [12]. In contrast to the in vitro 
experimental part of the study by Graff et al. [12], we observed 
a significant increase, and not a decrease, in TXB2 metabolite 
levels at TPV/r steady state, which persisted 48 hours following 
the last TPV/r dose. Differences in in vivo and in vitro study 
designs, research subjects, aggregometer, and reagents may 
account for some of the differences in the results. Further, Graff 
et al. [12] performed short time course experiments at 4 hours 
of in vivo dosing (results from 2 hours post-dosing indicated 
only non-statistically significant inhibition in collagen-
stimulated platelet aggregation) or at about 1.5 hours of in vitro 
treatment allowing for evaluation of dynamic changes in platelet 
aggregation. Tests conducted in this study include both 1-day 
treatment changes (24 hours after the first dosing) and also 
reflect the steady state pre-dosing measurements. Nevertheless, 
the absence of an effect of TPV/r on collagen- and ADP-
stimulated platelet function and the increase in urine TXB2 
metabolites in our study are robust and are supported by a larger 
Table 3.  Course and Change from Baseline in Biomarkers of Coagulation and Fibrinolysis With TPV/r 
 
Biomarker (Reference Range)    Baseline 
n = 21 
Day 1 
n = 21 
Day 10 
n = 16 
24 h After Last Dose 
n = 15 
48 h After Last Dose 
n = 15 
aPTT, s (22.8-31.0)  Mean 
p* 
24.9  24.37 
0.122 
22.46 
<0.0001 
22.01 
<0.0001 
22.19 
0.0002 
Prothrombin time, s (9.7-12.3)  Mean 
p* 
10.37  10.33 
0.438 
10.09 
0.019 
9.99 
0.0011 
9.98 
0.0009 
Fibrinogen, mg/dl (170-330)  Mean 
p* 
373.52  385.05 
0.476 
431.63 
0.0031 
458.6 
0.0004 
469.0 
0.006 
von Willebrand Factor antigen, % (> 49)  Mean 
p* 
153.71  166.62 
0.187 
196.94 
0.035 
197.07 
0.0085 
170.0 
0.0325 
Antithrombin III antigen, % (80-124)  Mean 
p* 
104.29  108.75 
0.107 
134.44 
<0.0001 
131.0 
<0.0001 
130.93 
<0.0001 
Antithrombin III activity, % (80-120)  Mean 
p* 
100.57  103.24 
0.062 
124.06 
<0.0001 
120.53 
<0.0001 
115.87 
<0.0001 
Factor II, % (50-200)  Mean 
p* 
110.38  107.48 
0.538 
129.19 
<0.0001 
122.40 
0.0753 
121.27 
0.0191 
Factor VII, % (50-200)  Mean 
p* 
106.81  103.81 
0.619 
135.38 
<0.0001 
135.00 
0.0041 
122.73 
0.0862 
Factor IX, % (50-200)  Mean 
p* 
87.29  81.86 
0.240 
99.56 
0.044 
102.13 
0.066 
104.87 
0.0147 
Factor X, % (50-200)  Mean 
p* 
112.10  110.57 
0.743 
124.94 
0.0006 
133.47 
0.0012 
125.33 
0.0164 
Plasminogen activity, %  Mean 
p* 
116.38  119.9 
0.009 
150.13 
<0.0001 
145.4 
0.002 
142.93 
0.0073 
-2 antiplasmin activity, %  Mean 
p* 
105.81  106.76 
0.351 
108.5 
0.169 
109.67 
0.187 
105.93 
0.669 
D-dimer, mg/dl  Mean 
p* 
1.7  1.78 
0.098 
1.42 
0.067 
1.36 
0.087 
1.34 
0.115 
PAI activity, IU/ml  Mean 
P* 
8.29  14.19 
0.014 
21.44 
0.0003 
17.33 
0.021 
16 
0.008 
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number of subjects (n = 21). Additionally, platelet viability and 
function was internally controlled for, as evidenced by the fact 
that several subjects had on-treatment abnormal AA-induced 
platelet aggregation and/or changes in PFA-100 CEPI CT, 
whereas concurrent collagen-, ADP- and PFA-100 collagen/ 
ADP-stimulated platelet aggregation function tests did not 
change from baseline. 
  Our results demonstrate that TPV/r specifically inhibits the 
pathway of AA-induced platelet aggregation in some, but not all 
subjects (e.g., in 43.8% for the primary endpoint at TPV/r 
steady state) while single-dose aspirin completely inhibited AA-
induced platelet aggregation in all subjects not allowing for 
correlation analysis between aspirin and TPV/r effects. The 
mechanism by which TPV/r inhibits AA-induced platelet 
Table 4.  Comparison of Changes in Platelet Function,* Coagulation, and Fibrinolytic Biomarkers by Treatment
† 
 
Mean Change from Baseline (SD) 
  
Day 1  Day 10 
TPV/r -290(804)  955  (1458) 
DRV/r  -31.42 (651)  232.6 (772)  Urinary TxB2 metabolites, pg/ml 
RTV -671(1799)  -456.21  (1473)
‡ 
TPV/r  92.05 (73.4)  56.06 (55.4) 
DRV/r -3.92  (15.2)
‡ 0.583  (14.0)
‡  PFA-100 CEPI CT, s 
RTV -11.17  (19.9)
‡  -6.58 (21.6)
‡ 
TPV/r  -0.52 (1.48)  -2.79 (1.75) 
DRV/r  -0.70 (2.22)  -1.5 (1.81)  aPTT, s 
RTV -2.44  (2.29)
‡ -2.53  (3.78) 
TPV/r  11.52 (72.8)  66.93 (76.1) 
DRV/r  33.16 (40.3)  46.91 (120)  Fibrinogen, mg/dl 
RTV  -40.25 (94.2)  -31.33 (118)
‡ 
TPV/r  12.90 (43.2)  46.5 (80.3) 
DRV/r  17.5 (20.9)  28.08 (64.8)  Von Willebrand factor antigen, % 
RTV  -17.25 (48/6)  -13.3 (50.0)
‡ 
TPV/r 2.66  (6.19)  25.5  (15.7) 
DRV/r  18.66 (35.7)  13.5 (14.3)
‡  Anti-thrombin III activity, % 
RTV  6.00 (29.6)  10.16 (13.3)
‡ 
TPV/r  4.28 (11.6)  30.75 (14.4) 
DRV/r  6.25 (8.48)  19.58 (6.89)
‡  Anti-thrombin III antigen, % 
RTV  0.41 (11.1)  22.58 (10.8) 
TPV/r  -2.90 (21.2)  19.5 (13.6) 
DRV/r 13.75  (16.8)
‡ 20.5  (16.2)  Factor II, % 
RTV  -3.19 (9.42)  8.5 (14.8) 
TPV/r  -1.52 (21.0)  11.43 (10.6) 
DRV/r  6.91 (15.6)  26.16 (13.7)
‡  Factor X, % 
RTV  -4.08 (14.2)  5.08 (14.0) 
TPV/r  3.52 (5.6)  31.6 (23.2) 
DRV/r  7.58 (11.2)  14.8 (16.2)
‡  Plasminogen activity, % 
RTV  4.75 (8.6)  21.0 (14.6) 
TPV/r  5.90 (10.0)  11.5 (9.8) 
DRV/r  2.25 (4.6)  6.83 (9.3)  PAI-1 activity (IU/ml) 
RTV  1.58 (6.3)  2.75 (10.2)
‡ 
*Excludes LTA tests. 
†Presented markers are limited to those that had at least one p value > 0.05. 
‡p<0.05; p-values represent 2-sided t-test for any difference in mean change from baseline of TPV/r and DRV/r or RTV. Effect of Tipranavir on Markers of Platelet Function  Current HIV Research, 2011, Vol. 9, No. 4    245 
aggregation is different from that of aspirin. Our observation 
that a single dose of aspirin substantially reduced TXB2 
metabolite levels in urine is consistent with its known inhibition 
of COX-1 [16] and is in contrast to the observed effect of TPV/r 
administration that resulted in elevated urine TXB2 metabolite 
levels. These findings are also consistent with a previous study 
in which 2 days of aspirin treatment reduced TXB2 serum levels 
in healthy volunteers by ~98% [14]. 
  Same-subject comparison of treatment with a single dose of 
aspirin versus TPV/r showed that aspirin significantly inhibited 
other platelet functions, including PF-100 CEPI CT and 
collagen-stimulated platelet aggregation, providing for a much 
broader and more potent inhibition of different pathways of 
platelet aggregation when compared with TPV/r. Again, our 
observed effects of aspirin on AA-induced platelet aggregation 
and collagen-induced platelet aggregation are in agreement with 
those of previous studies in which aspirin [14] or COX-1 
inhibitors [17,18] resulted in a profound (almost complete) 
inhibition of AA-induced platelet aggregation and inhibited 
collagen-induced platelet aggregation to a lesser extent (~50%) 
[14,18]. 
  However, reversible TPV/r effects on ex vivo measures of 
platelet aggregation which we observed in some of our healthy 
volunteers should be interpreted with caution and may not 
translate into a real increase for the risk of bleeding events or 
ICH in HIV-infected patients receiving TPV/r-based cART and 
which are susceptible to TPV/r’s effect on platelet aggregation. 
  First, platelet aggregation is a complex process that includes 
several independent pathways, each of which can fully activate 
platelets leading to aggregation. Results from this study show 
that TPV/r significantly affected the pathway of AA-induced 
platelet aggregation in only some of the healthy volunteers, 
leaving other pathways of platelet aggregation intact. We show 
that TPV/r’s effect on AA-induced platelet aggregation is not 
aspirin-like and factors that may predispose subjects to the 
inhibition of AA-stimulated platelet aggregation by TPV/r are 
not known. We demonstrated that aspirin is a more potent 
inhibitor of AA-induced platelet aggregation and, consistent 
with previous observations, significantly inhibited several 
pathways of platelet aggregation. 
  Second, the tested HIV protease inhibitors led to small 
changes in markers of coagulation and fibrinolysis that were 
variable in their extent and direction. From the multitude of 
markers tested, overall we have found only AA-induced platelet 
aggregation to be consistently and substantially changed by 
TPV/r in some individuals. We did not find any clinically 
important effect of TPV/r treatment on a panel of coagulation 
factors (including aPTT and prothrombin time), markers of 
fibrinolysis and bleeding time that would suggest TPV/r causes 
deficiencies in coagulation factors or hemostasis mechanisms, 
including fibrinolysis, which could increase the risk of bleeding. 
Previous analysis of plasma samples from 87 patients from the 
RESIST trial that showed no difference in vitamin K-dependent 
factor levels in patients treated with TPV/r (n = 54) versus those 
receiving comparator PI/r (n = 30) [11] is consistent with our 
finding of absence of clinically important TPV/r effects on 
studied coagulation factors. 
  Third, the risk of bleeding, including ICH, is increased in 
individuals with HIV infection, and appears to be further 
increased in persons with AIDS [7,8,10,19-21]. This higher risk 
of bleeding occurs despite increased platelet activation [22], 
increased von Willebrand antigen levels [23], and the state of 
increased inflammation [24], collectively providing for a 
prothrombotic milieu in HIV infection [25]. Long-term 
suppressive antiretroviral therapy is associated with toxicities 
and does not completely reverse the inflammatory state and 
defects caused by HIV, which result in accelerated aging 
manifested by premature onset of cardiovascular disease, 
neurocognitive impairment, osteoporosis, and non–AIDS-
related cancer [1,3,26-29]. The risk of ICH is increased with 
increased age, and patients on long-term antiretroviral therapy 
have an increased risk for ICH when compared with an age-
matched population [9,10,30]. 
  Finally, there is lack of clinical evidence that TPV/r 
increases the incidence of adverse bleeding or ICH. In 
clinical trials of TPV/r versus comparator PI/r, the incidence 
of adverse bleeding events (at any site) was 6.2 versus 
5.1/100 person-years of exposure, respectively, with a risk 
ratio of 1.2 (95% CI, 0.78-1.80 (Boehringer Ingelheim: data 
on file). In prospective clinical trials, the incidence of ICH in 
TPV/r-treated patients was similar to that of HIV-infected 
patients in the pre-TPV era [9,10]. Exposure to any 
particular class of antiretroviral has not been found to 
increase the risk of ICH in a small but well-designed case-
control study of 29 HIV-positive people with ICH and 
matched HIV-positive controls without ICH [20]. Eighty-
eight percent of patients who developed an ICH in trials with 
TPV/r had AIDS. Furthermore, all patients who developed 
ICH in TPV/r trials had comorbid conditions such as CNS 
infection, cardiovascular disease, liver disease, or other 
conditions, and/or received concomitant anti-platelet or anti-
coagulation therapy, all of which are known individual risk 
factors for ICH. Even though the platelet studies do not 
provide evidence for an increased risk for ICH that can be 
attributed to TPV/r therapy, TPV coadministered with low-
dose RTV should be used with caution in patients who may 
be at risk of increased bleeding from trauma, surgery, or 
other medical conditions, or who are receiving medications 
known to increase the risk of bleeding, such as antiplatelet 
agents and anticoagulants, or who are taking high doses of 
vitamin E. 
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